SCHEMBL13600644

SCHEMBL13600644

COc1c(Cl)cc(C(=O)NC[C@@H]2CCNC[C@H]2O)c2c1OCCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 3/20 0.43
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
DRD2 P14416 5/20 0.39
DRD3 P35462 3/20 0.39
DRD4 P21917 2/20 0.37
HTR3A P46098 2/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
SLC6A3 Q01959 2/20 0.36
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13607553 1.00 HTR4 (0.43) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13607704 0.96 HTR4 (0.42) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13600653 0.96 HTR4 (0.42) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13600711 0.90 HTR4 (0.43) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13607643 0.90 HTR4 (0.43) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13607404 0.86 HTR4 (0.42) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13600697 0.86 HTR4 (0.42) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13349282 0.83 CHRM1 (0.39) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13315500 0.83 CHRM1 (0.39) HTR4CHRM2CHRM4CHRM1CHRM3
SCHEMBL13349252 0.82 CHRM1 (0.38) HTR4CHRM2CHRM4CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635706-B2 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity JANSSEN PHARMACEUTICA NV (BE) 2009-12-22 US disclosed
US-20070032486-A1 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides JANSSEN PHARMACEUTICA NV (BE) 2007-02-08 US disclosed
US-20070032486-A1 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides JANSSEN PHARMACEUTICA NV (BE) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032486-A1 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides HTR4, HTR2B, TPH2 HTR4 1/4885CHRM2 145/4885CHRM4 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.